Beyond the Database: Turning Clinical Trial Data Into Strategic Advantage
Panel discussion summary
Clinical trial data is more than a regulatory deliverable — it is a long-term strategic asset. This panel explores how early- and mid-stage biotech companies can move beyond database lock and build data infrastructures that enable scientific insight, cross-trial integration, and commercial leverage. Learn how structured data governance strengthens decision-making, accelerates partnerships, and directly impacts company valuation in competitive markets.
Moderation
| Name | Position | Institution |
|---|---|---|
| Cornelia Baumgartner | Owner and Founder of Cetacea Clinical | Cetacea Clinical GmbH |
Panelists
| Name | Position | Institution |
|---|---|---|
| Dr. Ulf Grawunder | CEO | T-CURX GmbH |
| Elisabeth Steiger | Senior Director Clinical Data ManagemenT | Metronomia GmbH |
| Royden James | Chief Product Officer | Viedoc |
| Dr. Günter Fingerle- Rowson | Chief Medical Officer | Tubulis Inc. |
Metronomia GmbH
Metronomia is a European biometrics-focused CRO providing high-quality biostatistics, statistical programming, data management, and medical writing services to biotech and pharmaceutical companies. The company supports Phase I–III clinical trials across multiple therapeutic areas, delivering regulatory-ready data packages aligned with global authority expectations.
Metronomia positions itself as a science-driven partner, emphasizing senior expertise, methodological rigor, and close collaboration with sponsors. Its integrated biometrics model ensures data integrity, statistical robustness, and efficient submission preparation — strengthenin
Host and event manager:
Logistics and marketing partner:
